Antibiotic effects on gut microbiota modulate diet‐induced metabolic dysfunction‐associated steatohepatitis development in C57BL/6 mice
Genes to Cells · 2024
DOI: 10.1111/gtc.13134 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes to Cells, 2024. Verfasst von Shun Takano und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Engineering, Faculty of Engineering, Toyama Prefectural University, Imizu, Japan. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Mice, Inbred C57BL, Anti-Bacterial Agents, Vancomycin. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science, Toyama Pharmaceutical Valley Development Consortium.
Abstract (Originalsprache)
The potential involvement of the gut microbiota in metabolic dysfunction‐associated steatohepatitis (MASH) pathogenesis has garnered increasing attention. In this study, we elucidated the link between high‐fat/cholesterol/cholate‐based (iHFC)#2 diet‐induced MASH progression and gut microbiota in C57BL/6 mice using antibiotic treatments. Treatment with vancomycin (VCM), which targets gram‐positive bacteria, exacerbated the progression of liver damage, steatosis, and fibrosis in iHFC#2‐fed C57BL/6 mice. The expression levels of inflammation‐ and fibrosis‐related genes in the liver significantly increased after VCM treatment for 8 weeks. F4/80 + macrophage abundance increased in the livers of VCM‐treated mice. These changes were rarely observed in the iHFC#2‐fed C57BL/6 mice treated with metronidazole, which targets anaerobic bacteria. A16S rRNA sequence analysis revealed a significant decrease in α‐diversity in VCM‐treated mice compared with that in placebo‐treated mice, with Bacteroidetes and Firmicutes significantly decreased, while Proteobacteria and Verrucomicrobia increased markedly. Finally, VCM treatment dramatically altered the level and balance of bile acid (BA) composition in iHFC#2‐fed C57BL/6 mice. Thus, the VCM‐mediated exacerbation of MASH progression depends on the interaction between the gut microbiota, BA metabolism, and inflammatory responses in the livers of iHFC#2‐fed C57BL/6 mice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Engineering, Faculty of Engineering, Toyama Prefectural University, Imizu, Japan.
- Department of Pathology and Laboratory Medicine, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
- Institute of Natural Medicine, University of Toyama, Toyama, Japan.
ORCID-Profile: Yoshinori Nagai
Förderung
- Japan Society for the Promotion of Science
- Toyama Pharmaceutical Valley Development Consortium
Zitieren
APA
Takano, S., Kani, K., Kasai, K., Igarashi, N., Kato, M., Goto, K., Matsuura, Y., Ichimura-Shimizu, M., Watanabe, S., Tsuneyama, K., Furusawa, Y., & Nagai, Y. (2024). Antibiotic effects on gut microbiota modulate diet‐induced metabolic dysfunction‐associated steatohepatitis development in C57BL/6 mice. Genes to Cells. https://doi.org/10.1111/gtc.13134
Vancouver
Takano S, Kani K, Kasai K, Igarashi N, Kato M, Goto K, et al. Antibiotic effects on gut microbiota modulate diet‐induced metabolic dysfunction‐associated steatohepatitis development in C57BL/6 mice. Genes to Cells. 2024. doi:10.1111/gtc.13134
BibTeX
@article{Takano2024,
author = {Takano, Shun and Kani, Koudai and Kasai, Kaichi and Igarashi, Naoya and Kato, Miyuna and Goto, Kana and Matsuura, Yudai and Ichimura-Shimizu, Mayuko and Watanabe, Shiro and Tsuneyama, Koichi and Furusawa, Yukihiro and Nagai, Yoshinori},
title = {Antibiotic effects on gut microbiota modulate diet‐induced metabolic dysfunction‐associated steatohepatitis development in C57BL/6 mice},
journal = {Genes to Cells},
year = {2024},
doi = {10.1111/gtc.13134}
}
EUVIMED